These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6. Blennow M; Granström M; Olin P; Tiru M; Jäätmaa E; Askelöf P; Sato Y Dev Biol Stand; 1986; 65():185-90. PubMed ID: 3549397 [TBL] [Abstract][Full Text] [Related]
3. Invasive bacterial infections during an efficacy trial of acellular pertussis vaccines--implications for future surveillance in pertussis vaccine programmes. Olin P; Romanus V; Storsaeter J Tokai J Exp Clin Med; 1988; 13 Suppl():143-4. PubMed ID: 3078803 [TBL] [Abstract][Full Text] [Related]
4. Acellular pertussis vaccines: new preparation. Better tolerated but less active? Prescrire Int; 2000 Feb; 9(45):204-7. PubMed ID: 11503797 [TBL] [Abstract][Full Text] [Related]
5. Combined acellular pertussis vaccines: new indication. No tangible benefit in primary vaccination. Prescrire Int; 2002 Jun; 11(59):73-5. PubMed ID: 12068840 [TBL] [Abstract][Full Text] [Related]
6. Tolerability of the Biken acellular pertussis vaccine in adults with or without previous vaccination against pertussis in childhood. Knuf M; Schmitt HJ; Mohnike K; Zepp F; Habermehl P; Kampmann C; Herden P Med Klin (Munich); 2004 Sep; 99(9):495-9. PubMed ID: 15372178 [TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. Keitel WA; Muenz LR; Decker MD; Englund JA; Mink CM; Blumberg DA; Edwards KM J Infect Dis; 1999 Aug; 180(2):397-403. PubMed ID: 10395855 [TBL] [Abstract][Full Text] [Related]
8. Efficacy trial of acellular pertussis vaccines; trial I. Olin P Dev Biol Stand; 1997; 89():52-4. PubMed ID: 9333569 [No Abstract] [Full Text] [Related]
10. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine. Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522 [TBL] [Abstract][Full Text] [Related]
11. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Ward JI; Cherry JD; Chang SJ; Partridge S; Keitel W; Edwards K; Lee M; Treanor J; Greenberg DP; Barenkamp S; Bernstein DI; Edelman R; Clin Infect Dis; 2006 Jul; 43(2):151-7. PubMed ID: 16779740 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995 [TBL] [Abstract][Full Text] [Related]
13. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Stehr K; Cherry JD Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571 [No Abstract] [Full Text] [Related]
14. Sénégal pertussis trial. Simondon F Dev Biol Stand; 1997; 89():63-6. PubMed ID: 9333572 [No Abstract] [Full Text] [Related]
15. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. Knuf M; Schmitt HJ; Wolter J; Schuerman L; Jacquet JM; Kieninger D; Siegrist CA; Zepp F J Pediatr; 2008 May; 152(5):655-60, 660.e1. PubMed ID: 18410769 [TBL] [Abstract][Full Text] [Related]
16. Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Olin P; Hallander HO; Gustafsson L; Barreto L; Podda A Dev Biol Stand; 1998; 95():211-20. PubMed ID: 9855434 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Gustafsson L; Hessel L; Storsaeter J; Olin P Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988 [TBL] [Abstract][Full Text] [Related]
19. Composition of acellular pertussis and combination vaccines: a general review. Jadhav SS; Gairola S Biologicals; 1999 Jun; 27(2):105-10. PubMed ID: 10600195 [TBL] [Abstract][Full Text] [Related]
20. [The immunological basis of the administration of DTP-polio vaccine]. Cohen H Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]